News

September 13th, 2019

Biogen and Eisai Abandon BACE Inhibitor Program in Alzheimer’s Disease

“Today marks what is likely to be viewed as yet another nail in the coffin of the beta-amyloid theory. Biogen and Eisai announced they were discontinuing their Phase III trials, MISSION AD1 and AD2, evaluating an investigational oral BACE inhibitor elenbecestat in patients with early Alzheimer’s disease. The Data Safety Monitoring Board (DSMB) ran a safety review and recommended the trials end because of an unfavorable risk-benefit ratio.”


Maria Ali

May 14th, 2019

It has been a tremendous privilege working alongside my Scientific Advisory Board for the last two years: Dr. Brian Balin, Dr. David Hahn, Dr. Alan Hudson, Dr. Judith Whittum-Hudson, Dr. Charles Stratton, and Dr. Wilmore Webley. With great excitement, we announce the addition of Dr. Maria Ali to our Team. Maria is the Chief Medical Officer for George Clinical (CRO) and brings clinical trial design and efficiency expertise to our group. We are so grateful to be working with her!


National Institutes of Health (NIH) - Turning Discovery into Health

April 8th, 2019

The National Institute on Aging (NIA) has decided to allocate a new pool of funds for Infectious Alzheimer’s Research. This marks the beginning of an important shift that will impact so much more than this one disease.

“Infectious Etiology of Alzheimer’s Disease: This high-priority topic aims to: (1) determine whether microbial pathogens represent a causal component of Alzheimer’s disease (AD), (2) establish mechanisms by which microbial pathogens impact neurodegenerative processes in AD, and (3) inform aspects of future translational studies in AD, including discovery of candidate therapeutics aimed at regulating pathogen-associated networks and molecules in AD.”


January 31st, 2019

“Roche halts phase 3 anti-Abeta Alzheimer’s test as AD flops rack up”

It is time to pursue the infection hypothesis in AD. Amyloid beta is an antimicrobial peptide made by the body to combat infection. Intracell Research Group has a plan for a prospective trial in early dementia. A product of pulling experts in chronic infection together from various disciplines to come up with a solid, evidence-based, INNOVATIVE plan. We are in this to help people, working every day on getting it funded. We will not give up.


Screen Shot 2018-11-13 at 12.18.07 PM

December 20th, 2018

“Alzheimer’s Germ Quest, Inc., an independent Alzheimer’s disease research advocacy organization, has launched “10% for Germs”, a grassroots citizens, patients, and caregivers campaign to demand the National Institutes of Health (NIH) immediately allocate $230 million for research grants to determine the roles of germs in causing Alzheimer’s, announced its CEO, Leslie Norins, M.D, Ph.D. ”


Screen Shot 2018-11-13 at 12.18.07 PM

November 13th, 2018

Dr. Leslie Norins has pledged a $1 million prize to the team that can prove Alzheimer’s is being driven by infection. Last month he and Dr. Judith Miklossy hosted a conference in Switzerland with presentations from over 25 physicians and researchers working in this field. innovationbackedbyscience infectiousalzheimers

Here is a complete agenda from the meeting with topics and speakers: Alzheimer’s Conference Agenda Switzerland 2018


Screen Shot 2018-11-13 at 12.04.53 PM

November 9th, 2018

The topic of Alzheimer’s and INFECTION is getting more and more attention. “It does not appear that therapeutics based on tau and amyloid are going to work, said Brian Balin, a neuropathologist who directs the Center for Chronic Disorders of Aging at Philadelphia College of Osteopathic Medicine, and has been studying the role of the Chlamydia pneumoniae bacteria in Alzheimer’s since 1998.” It is time to fund a large trial to test antimicrobials that address both bacteria and viruses. A 20-year-old body of research says so.


Screen Shot 2018-10-15 at 10.23.47 AM

October 15th, 2018

Respiratory Chlamydia Infection Induce Release of Hepoxilin A3 and Histamine Production by Airway Neutrophils

Katir K. Patel and Wilmore C. Webley

Published TODAY! Excellent work by Dr. Patel and Dr. Webley.  This research study is an invaluable clue in the correlation between chronic Chlamydia pneumoniae (CpN) infection and Asthma.  ” These findings suggest that neutrophils, provoked by Chlamydia infection can synthesize and release histamine, thereby contributing directly to airway inflammation.”  Read more research on this topic at www.intracellresearchgroup.com/Asthma #innovationbackedbyscience


TLN-1532516604703

October 4th, 2018

Hot off the press! Lancet Neurology. A response by two infectious Alzheimer’s experts to the recent publication correlating HSV1 to AD. Well said Dr. Balin and Dr. Hudson, it’s a privilege to work with you on this worthy cause.

“With the focus having been on amyloid-β and tau for the past 30 years and more, we contend that answers to the questions of Alzheimer’s disease, and possibly other neurodegenerative conditions as well, does not reside solely in the pathology, but rather in the route to that pathology, for which infectious agents provide biologically and pathologically relevant solutions.” #innovationbackedbyscience


September 25th, 2018

“If I have seen further it is by standing on the shoulders of giants.”
-Isaac Newton

On Sunday Intracell Research Group hosted its 12th Monthly Grand Rounds call. Why is this so special? The idea is simple; when people talk great things happen. By CONNECTING experts in chronic Chlamydia pneuomoniae infection with different disease focuses we are advancing faster and innovating better. Those researching and publishing on infectious Asthma, Arthritis, Alzheimer’s, MS and Cardiovascular Disease are SHARING and pressure testing each others ideas. The result of the last year of hard work and collaboration: 2 Research Grant submissions for infectious Alzheimer’s research, 1 ongoing collaborative in vitro study between an MS/ID/Micro expert and a Micro/Asthma expert, a CME conference in the works on the overall burden of intracellular infection, and countless relationships created. With our common goal we march forward, shining light on this incredibly important cause. #innovationbackedbyscience #intracellresearchgroup


Dr. Norins pledge to give $1 million as a reward to the team that proves Alzheimer’s is infectious is cool and innovative. The lack of mention of bacterial organisms in this NPR article is unfortunate. Like viruses they have been researched extensively in late-onset Alzheimer’s, particularly Chlamydia pneumoniae. A well-rounded approach to test the infection hypothesis in Alzheimer’s would be to have two antimicrobial study arms examining both antiviral and antibacterial regimens. Targeting one when there is substantial evidence for BOTH is risking yet another failed trial in this disease state. That’s not healthy for proof of concept nor is it the best way to stimulate innovation and interest in this novel approach. To cover all known bases by acknowledging the whole body of infection research (20+ years of it) is comprehensive and most sensible. Patients deserve that.
“The Alzheimer’s gamble: NIH tries to turn billions in new funding into treatment for deadly brain disease”

NIH is allocating $2.9 billion to Alzheimer’s research in 2019. Will there be acknowledgement that Amyloid beta is an antimicrobial peptide? It’s perhaps the most meaningful and overlooked clue. Time to redirect funding toward the infection hypothesis.